Dataset Information


Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis.

ABSTRACT: Guidelines for treatment of metastatic pancreatic cancer recommend a second line based on Fluoropyrimidine (FP) alone or in combination with Oxaliplatin (OXA) or Irinotecan (IRI) after a first line treatment based on Gemcitabine (GEM). We conducted a Bayesian network meta-analysis to compare currently available therapies to treat metastatic pancreatic cancer in the second line, considering as efficacy measures overall survival (OS) and progression free survival (PFS). Published randomized trials were identified using electronic databases (MEDLINE, PubMed, https://clinicaltrials.gov/ and American Society of clinical oncology). 8 studies met the inclusion criteria for a total of 1,587 patients and 7 different therapeutic schemes. The results suggested that the use of IRI-FP-Folinic Acid scheme in the second-line treatment of metastatic pancreatic cancer may offer a benefit in terms of OS and PFS for patients not previously treated with these drugs.

PROVIDER: S-EPMC6049864 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC7878976 | BioStudies
| S-EPMC6640066 | BioStudies
| S-EPMC7338813 | BioStudies
| S-EPMC4075567 | BioStudies
| S-EPMC7533956 | BioStudies
| S-EPMC8555183 | BioStudies
| S-EPMC6197657 | BioStudies
| S-EPMC7158760 | BioStudies
| S-EPMC4821390 | BioStudies
| S-EPMC7028474 | BioStudies